Suggested remit: To appraise the clinical and cost effectiveness of ribociclib within its marketing authorisation for previously untreated advanced, hormone receptor-positive, HER2-negative breast cancer in premenopausal women.
Status In progress
Process STA pre-2018
ID number 1307

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
19 October 2017 - 16 November 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
19 October 2017 In progress, In progress

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance